Sign in Subscribe
Cancer research

Whole-Body Magnetic Resonance Imaging Enhances Staging Accuracy in Metastatic Hormone-Sensitive Prostate Cancer

Strategic Insights

— 1 min read

A new study has shed light on the benefits of using whole-body magnetic resonance imaging (WB-MRI) in detecting metastatic sites and disease classification in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Researchers at Portsmouth Hospitals University NHS Trust in the UK compared WB-MRI with computed tomography (CT) and bone scans in patients with mHSPC, finding that WB-MRI identified higher rates of bone-only disease and potentially influenced treatment decisions. The study's findings suggest that WB-MRI may optimize management in mHSPC, warranting further prospective validation.

Key Takeaways:

  • The study included 203 patients with mHSPC, with 120 undergoing WB-MRI and 83 undergoing CT-B.
  • WB-MRI identified higher rates of bone-only disease (47% vs 22%, p < 0.001) and potentially influenced treatment decisions.
  • The study suggests that WB-MRI may optimize management in mHSPC, warranting further prospective validation.
  • The research used CHAARTED and LATITUDE criteria for disease classification.
  • Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses.
  • The study was conducted at 2 UK NHS hospitals over a period of 6 years (2017-2023).
  • The researchers used data on demographics, disease extent, and treatment in the analysis.
  • The study's findings have implications for the management of mHSPC, with potential benefits for patient outcomes.

Statistics:

  • 203 patients with mHSPC were included in the study.
  • 120 patients underwent WB-MRI and 83 underwent CT-B.
  • WB-MRI identified 47% of patients with bone-only disease, compared to 22% with CT-B.
  • The study's findings demonstrate a significant difference in staging accuracy between WB-MRI and CT-B.

Sources:

  • "Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone-Sensitive Prostate Cancer." Clinical Medicine Insights: Oncology, vol. 19, 2025, http://insights.sagepub.com/journal.php?journal_id=42&issue_id=411.
  • Portsmouth Hospitals University NHS Trust, "Department of Oncology", Portsmouth, United Kingdom, EU.

Read more